Showing results (141-150 of 182) with videos related to
Sort By:
Pageof 19
International Journal of Colorectal Disease|March 5, 2009
Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapyV Moreno García, P Cejas, M Blanco Codesido, et al.Archivos Espanoles De Urologia|July 1, 1996
[Lymphomas of the urinary tract]J M Rodríguez de Ledesma, J López-Tello, J de Castro, et al.Fundamental & Clinical Pharmacology|January 1, 1995
Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodologyI R de Oliveira, R M Dardennes, E S Amorim, et al.Cell|October 5, 2010
Systematic protein location mapping reveals five principal chromatin types in Drosophila cellsGuillaume J Filion, Joke G van Bemmel, Ulrich Braunschweig, et al.Oncogene|May 1, 2012
IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancerM Cortés-Sempere, M P de Miguel, O Pernía, et al.British Journal of Cancer|March 23, 2006
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancerJ Feliu, A Salud, P Escudero, et al.Oncogene|February 8, 2006
MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancerS Chattopadhyay, R Machado-Pinilla, C Manguan-García, et al.Current Cancer Drug Targets|January 11, 2012
Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapyP Cejas, M López-Gómez, C Aguayo, et al.ESMO Open|January 18, 2022
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancerJ Wolf, Å Helland, I-J Oh, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 23, 2020
Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapyD Viñal, L Gutierrez-Sainz, D Martinez, et al.Pageof 19